Cohance Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot

External CEO appointedManagement Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.5%Reaction day

₹444.90

prior close

₹449.80

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-4.1% vs market

Pharmaceuticals peers, median of 160sector-0.1%-4.3% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Smallcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.9

10m

-2.7

15m

-3.7

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.5-0.4-4.1-0.1-4.3

Next day

-3.6-1.9-1.7-0.9-2.7

-4.0-0.7-3.3-0.2-3.8

-5.7-0.7-5.0+0.3-6.0

-5.5+0.0-5.6+1.1-6.6

-6.0-0.1-6.0+0.2-6.2

-2.7+1.3-4.0+1.0-3.6

15d

-4.7-0.2-4.5-0.2-4.5

-4.4+3.0-7.4+1.7-6.1

-2.5+7.8-10.2+7.9-10.3

+0.5+9.1-8.6+8.1-7.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences Limited is seeking shareholder approval via postal ballot for appointing Mr. Umang Vohra as Chairman (effective May 1, 2026) and Group Chief Executive Officer (effective May 20, 2026). Mr. Vohra joins from Cipla Limited where he served as Managing Director and Global CEO for over 10 years, with prior experience at Dr. Reddy's Laboratories as CFO and head of North America generics. The company also seeks approval to pay him remuneration exceeding statutory limits under Section 197 of the Companies Act. Additionally, shareholders are asked to approve a new Employee Stock Option Plan 2026 (ESOP 2026) covering up to 2,59,18,613 equity shares, its extension to unlisted subsidiaries, and grants exceeding 1% of issued capital in a single financial year. Voting period runs from May 15 to June 13, 2026.

Likely market impact

This is a significant leadership transition bringing an experienced pharmaceutical executive to drive company transformation. The large ESOP pool signals retention focus but will dilute shareholder value. The 1% annual grant threshold for Mr. Vohra represents substantial equity compensation.